Combination therapy of radiopharmaceuticals and checkpoint inhibitors targeting PSMA
By combining 225Ac-radiogenic drugs with checkpoint inhibitors, targeting PSMA-positive cancer cells, the problems of low efficacy and major side effects in the prior art are solved, efficient treatment of specific cancers is achieved, and tumor volume and prolongation are reduced. Survival rate.
Patent Information
- Application Number
- CN202380029880.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-01-28
- Filing Date
- 2023-01-27
- Publication Date
- 2024-11-12
AI Technical Summary
Existing cancer treatments lead to activation of the immune system through checkpoint inhibitors. Although it can improve the attack on cancer cells, it can also cause side effects on normal cells and have limited efficacy, especially in most cancer types, with a low response rate. .
Combining radiopharmaceuticals and checkpoint inhibitors, targeting prostate-specific membrane antigen (PSMA)-positive tumors with 225Ac-radiopharmaceuticals, inhibited by 225Ac-radiopharmaceuticals with checkpoint inhibitors (such as PD-1 or CTLA-4 (co-administered agents) enhance the killing effect on cancer cells and reduce the toxicity to normal cells.
It improves the therapeutic effect of specific types of cancers such as prostate cancer, reduces side effects, significantly reduces or stabilizes tumor volume, prolongs patient survival, and reduces the risk of cancer recurrence and metastasis.
Smart Images

Figure CN118946371A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of U.S. Provisional Patent Application No. 63 / 304,181, filed on January 28, 2022, the entire contents of which are incorporated herein by reference. Background Art
[0003] Cancer cells use various mechanisms to escape immune surveillance, including suppression of T cell activation.
[0004] The mammalian immune system relies on checkpoint molecules to distinguish between normal cells and foreign cells. Checkpoint molecules expressed on certain immune cells need to be activated or inactivated to initiate an immune response. Inhibition of checkpoint proteins leads to increased activation of the immune system.
[0005] Checkpoint inhibition has been explored as an approach to cancer immunotherapy. Upregulation of checkpoint molecules such as programmed death 1 (PD-1), programmed death ligand-1 (PD-L1), and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) is naturally meant to limit the extent of tumor-specific immune responses. Blocking these checkpoint molecules therefore results in more robust and durable T cell activation. However, checkpoint inhibition also enables the immune system to attack some normal cells in the body, leading to harmful side effects. In addition, only a limited number of cancer types, such as melanoma, lung cancer, bladder cancer, and head and neck tumors, show inherent sensitivity to checkpoint inhibition. Within responsive tumor types, the typical overall response rate for patients is only 20%-25%.
[0006] Therefore, there is a need for improved cancer treatments. In particular, there is a need to increase efficacy without increasing toxicity to the patient. Summary of the invention
[0007] The present invention includes the recognition that combining inhibition of checkpoint proteins with therapies that target cancer cell damage can provide treatments with lower toxicity and better efficacy. Radioactive decay can cause direct physical damage (e.g., single-strand or double-strand DNA breaks) or indirect damage (e.g., bystander effect or crossfire effect) to the biomolecules that make up the cell. Drugs that deliver radionuclides to cancer cells, i.e., radiopharmaceuticals, provide a mechanism for producing DNA damage and anti-cancer therapeutic effects. The present invention provides 225 Combination of Ac-radioactive drugs and checkpoint inhibitors to treat or ameliorate cancer, 225 Ac-radiopharmaceuticals are specifically small molecule based radiopharmaceuticals that target prostate specific membrane antigen (PSMA) positive tumors and cancer cells using actinium-225.
[0008] More specifically, provided is a method of treating a mammal having a cancer that expresses prostate specific membrane antigen (PSMA), the method comprising:
[0009] (i) administering to the mammal 225 Ac-radiopharmaceutical, wherein the mammal has received or is receiving one or more checkpoint inhibitors;
[0010] (ii) administering one or more checkpoint inhibitors to the mammal, wherein the mammal has received or is receiving 225 Ac-radiopharmaceutical; or
[0011] (iii) administering to the mammal 225 Ac-radiopharmaceutical and administering one or more checkpoint inhibitors to the mammal simultaneously.
[0012] wherein in each case, the 225 Ac-radiopharmaceuticals comprise a compound of formula I or a stereoisomer thereof chelated with 225 Ac:
[0013]
[0014] In some embodiments, the method comprises administering one or more checkpoint inhibitors to the mammal, wherein the mammal has received or is receiving 225 Ac-radiopharmaceutical.
[0015] In some embodiments, the method comprises administering to the mammal 225 Ac-radiopharmaceutical, wherein the mammal has received or is receiving one or more checkpoint inhibitors.
[0016] In some embodiments, the method comprises administering to the mammal 225 One or more checkpoint inhibitors are administered to the mammal simultaneously with the Ac-radiopharmaceutical.
[0017] In some embodiments, the chelator is selected from the group consisting of: DOTA, DOTA-GA, NOTA, NODA-GA, and NODA-SA.
[0018] In some embodiments, the chelating agent is selected from the group consisting of: DOTA, EDTA, CDTA, DFO, BAT and HYNIC.
[0019] In some embodiments, the 225 Ac-radiopharmaceuticals include chelated 225 Ac:
[0020]
[0021] In some embodiments, the one or more checkpoint inhibitors include a PD-1 or PD-L1 inhibitor or a CTLA-4 inhibitor.
[0022] In some embodiments, the PD-1 or PD-L1 inhibitor or the CTLA-4 inhibitor is an antibody.
[0023] In some embodiments, the one or more checkpoint inhibitors include a PD-1 or PD-L1 inhibitor and a CTLA-4 inhibitor.
[0024] In some embodiments, the PD-1 or PD-L1 inhibitor is selected from: camrelizumab, cemiiplumab, dostarlimab, nivolumab, pembrolizumab, sintilimab, tislelizumab, toripalimab, RMP1-14, atezolizumab, avelumab, and durvalumab.
[0025] In some embodiments, the CTLA-4 inhibitor is selected from: BMS-986218, BMS-986249, ipilimumab, tremelimumab (formerly known as ticilimumab, CP-675,206), MK-1308, REGN-4659 and 4F10-11.
[0026] In some embodiments, the mammal is a human.
[0027] In some embodiments, the 225 The Ac-radiopharmaceutical is administered at a dose of less than 2 MBq / kg body weight of said mammal.
[0028] In some embodiments, the 225 The Ac-radiopharmaceutical is administered at a dose of less than 1 MBq / kg body weight of said mammal.
[0029] In some embodiments, the 225 The Ac-radiopharmaceutical is administered at a dose of less than 750 kBq / kg body weight of said mammal.
[0030] In some embodiments, the 225The Ac-radiopharmaceutical is administered at a dose of less than 500 kBq / kg body weight of said mammal.
[0031] In some embodiments, the 225 The Ac-radiopharmaceutical is administered at a dose of less than 250 kBq / kg body weight of said mammal.
[0032] In some embodiments, the 225 The Ac-radiopharmaceutical is administered at a dose of less than 100 kBq / kg body weight of said mammal.
[0033] In some embodiments, the 225 The Ac-radiopharmaceutical is administered to the mammal in a unit dose of less than 15 MBq.
[0034] In some embodiments, the 225 The Ac-radiopharmaceutical is administered to the mammal in a unit dose of less than 10 MBq.
[0035] In some embodiments, the 225 The Ac-radiopharmaceutical is administered to the mammal in a unit dose of less than 5 MBq.
[0036] In some embodiments, the checkpoint inhibitor is administered at a dose of about 1 mg / kg to about 10 mg / kg body weight of the mammal.
[0037] In some embodiments, the checkpoint inhibitor is administered at a dose of about 5 mg / kg body weight of the mammal.
[0038] In some embodiments, the cancer is selected from the group consisting of prostate cancer, breast cancer, colorectal cancer, renal cell carcinoma, bladder cancer, testicular embryonal carcinoma, neuroendocrine cancer, and a brain tumor.
[0039] In some embodiments, the cancer is prostate cancer or breast cancer.
[0040] In some embodiments, the administering results in a decrease in tumor volume, a stabilization of tumor volume, or a decrease in the rate of increase of tumor volume.
[0041] In some embodiments, the administering results in a reduced occurrence of recurrence or cancer metastasis.
[0042] In some embodiments, the method comprises administering to the mammal one or more checkpoint inhibitors, wherein the mammal has received or is receiving a regimen comprising a chelated 225 Ac 225 Ac-radiopharmaceuticals:
[0043]
[0044] The one or more checkpoint inhibitors include PD-1 inhibitors and CTLA-4 inhibitors, and the 225 The Ac-radiopharmaceutical is administered at a dose of 0.5-1.5 MBq / kg body weight of said mammal.
[0045] The present invention also provides the use of a compound of formula I in the manufacture of a medicament for use in a method of treating a mammal having a cancer expressing prostate-specific membrane antigen (PSMA) in a subject in need thereof, the method comprising:
[0046] (i) administering to the mammal 225 Ac-radiopharmaceutical, wherein the mammal has received or is receiving one or more checkpoint inhibitors;
[0047] (ii) administering one or more checkpoint inhibitors to the mammal, wherein the mammal has received or is receiving 225 Ac-radiopharmaceutical; or
[0048] (iii) administering to the mammal 225 Ac-radiopharmaceutical and administering one or more checkpoint inhibitors to the mammal simultaneously.
[0049] wherein in each case, the 225 Ac-radiopharmaceuticals comprise a compound of formula I or a stereoisomer thereof chelated with 225 Ac:
[0050]
[0051] In another aspect, provided herein is a compound of Formula I for use in treating a mammal having a cancer expressing prostate-specific membrane antigen (PSMA) in a subject in need thereof, the method comprising:
[0052] (i) administering to the mammal 225 Ac-radiopharmaceutical, wherein the mammal has received or is receiving one or more checkpoint inhibitors;
[0053] (ii) administering one or more checkpoint inhibitors to the mammal, wherein the mammal has received or is receiving 225 Ac-radiopharmaceutical; or
[0054] (iii) administering to the mammal 225 Ac-radiopharmaceutical and administering one or more checkpoint inhibitors to the mammal simultaneously.
[0055] wherein in each case, the225 Ac-radiopharmaceuticals comprise a compound of formula I or a stereoisomer thereof chelated with 225 Ac:
[0056] BRIEF DESCRIPTION OF THE DRAWINGS
[0057] Figure 1 The results showed that the radiopharmaceuticals in the CT-26 syngeneic model [ 177 Lu]-Biodistribution of Compound A.
[0058] Figure 2 Different doses of radiopharmaceuticals in the CT-26-mFOLH1 isogenic immunocompetent mouse model are described. 225 Ac]-In vivo efficacy of Compound A.
[0059] Figure 3A and Figure 3B The results showed that in the CT-26-mFOLH1 syngeneic mouse model, the radiopharmaceutical [ 225 Ac]-Compound A combined with α-CTLA-4 / PD-1 improves the therapeutic effect.
[0060] Figure 4A and Figure 4B It is explained in [ 225 Ac]-Compound A-treated mice showed improvement in overall survival. DETAILED DESCRIPTION OF THE INVENTION
[0062] The present invention relates to a combination therapy for treating cancer using certain radiopharmaceuticals and checkpoint inhibitors. In particular, the radiopharmaceutical is a prostate-specific membrane antigen (PSMA)-targeting 225 Ac chelated small molecules.
[0063] Radiolabeled targeting moieties (also called radiopharmaceuticals) are designed to target proteins or receptors (e.g., PSMA) that are upregulated in disease states and / or specific to diseased cells (e.g., tumor cells) to deliver a radioactive payload to damage and kill the relevant cells.
[0064] definition
[0065] Chemical terms
[0066] As used herein, the term "isomer" refers to any tautomer, stereoisomer, enantiomer or diastereomer of any compound. It should be recognized that the compounds of Formula I have one or more chiral centers and can therefore exist in stereoisomeric forms, such as diastereomers (e.g., enantiomers (i.e., (+) or (-))). Unless otherwise indicated, the chemical structures described herein include all corresponding stereoisomers, i.e., stereoisomerically pure forms (e.g., geometrically pure forms, enantiomerically pure forms, or diastereomerically pure forms) and enantiomers and stereoisomer mixtures, such as racemates. Enantiomers and stereoisomeric mixtures of compounds can generally be resolved into their component enantiomers or stereoisomers by well-known methods, such as chiral phase gas chromatography, chiral phase high performance liquid chromatography, crystallization of the compound as a chiral salt complex, or crystallization of the compound in a chiral solvent. Enantiomers and stereoisomers may also be obtained from stereoisomerically or enantiomerically pure intermediates, reagents and catalysts by well-known asymmetric synthetic methods.
[0067] As used herein, the term "stereoisomer" refers to all possible different isomeric forms and conformational forms that a compound (e.g., a compound of any formula described herein) may have, in particular all possible stereochemical and conformational isomeric forms of the basic molecular structure, all diastereomers, enantiomers and / or conformational isomers. Some compounds may exist in different tautomeric forms, all of which are included within the scope of the present invention.
[0068] As used herein, the term "diastereomer" refers to stereoisomers that are not mirror images of each other and are non-superimposable.
[0069] As used herein, the term "enantiomer" refers to each individual optically active form of a compound having an optical purity or enantiomeric excess (determined by standard methods in the art) of at least 80% (i.e., at least 90% of one enantiomer and up to 10% of the other enantiomer), preferably at least 90% and more preferably at least 98%.
[0070] Other terms
[0071] As used herein, unless otherwise specified or inferred from the context, the term "about" or "approximately" refers to ±10% variation relative to the stated quantitative value (and including the stated quantitative value itself). For example, unless otherwise specified or inferred from the context, a dose of about 100 kBq / kg represents 100±10% kBq / kg, i.e., a dose range of 90 kBq / kg to 110 kBq / kg (including 90 kBq / kg and 110 kBq / kg), including the endpoint values.
[0072] As used herein, the term "combination administration", "co-administration" or "co-administration" refers to the administration of two or more drugs to a subject simultaneously or within a time interval so that the effect of each drug on the patient may overlap. Therefore, two or more drugs administered in combination do not need to be administered together. In some embodiments, within 90 days (e.g., within 80, 70, 60, 50, 40, 30, 20, 10, 5, 4, 3, 2 or 1 day), within 28 days (e.g., within 14, 7, 6, 5, 4, 3, 2 or 1 day), within 24 hours (e.g., 12, 6, 5, 4, 3, 2 or 1 hour), or within about 60, 30, 15, 10, 5 or 1 minute. In some embodiments, the dosing intervals of the drugs are close enough to achieve a combined effect.
[0073] As used herein, "administering" a drug to a subject includes contacting cells of the subject with the drug.
[0074] The term "cancer" refers to any cancer caused by the proliferation of malignant cells, such as tumors, neoplasms, carcinomas, sarcomas, leukemias and lymphomas. "Solid tumor cancers" are cancers that include abnormal tissue masses, such as sarcomas, carcinomas and lymphomas. As used interchangeably herein, "blood cancers" or "liquid cancers" are cancers that are present in body fluids, such as lymphomas and leukemias.
[0075] The term "checkpoint inhibitor," also known as "immune checkpoint inhibitor" or "ICI," refers to drugs that block the action of immune checkpoint proteins, such as by blocking these immune checkpoint proteins from binding to their partner proteins.
[0076] As used herein, the term "chelate" refers to an organic compound or a portion thereof that can bond to a central metal or radiometal atom at two or more points.
[0077] As used herein, the term "conjugate" refers to a molecule containing a chelating group or a metal complex thereof, a linking group, and optionally a therapeutic moiety or a targeting moiety.
[0078] As used herein, the term "compound" is intended to include all stereoisomers, geometric isomers, and tautomers of the depicted structure.
[0079] The compounds described herein may be asymmetric (e.g., have one or more stereocenters). Unless otherwise indicated, all stereoisomers, such as enantiomers and diastereomers, are referred to. Compounds of the present invention containing asymmetrically substituted carbon atoms can be separated in optically active or racemic forms. Methods for preparing optically active forms from optically active starting materials are known in the art, such as by resolving racemic mixtures or stereoselective synthesis. Multiple geometric isomers of alkenes, C=N double bonds, and the like may also be present in the compounds described herein, and all such stable isomers are included in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be separated as isomeric mixtures or as separated isomeric forms.
[0080] The compounds of the present invention also include tautomeric forms. Tautomeric forms are produced by the exchange of a single bond with an adjacent double bond and the concomitant migration of a proton. Tautomeric forms include prototropic tautomers, which are isomeric protonation states with the same empirical formula and total charge. Examples of prototropic tautomers include keto-enol pairs, amide-imidic acid pairs, lactam-lactim pairs, amide-imidic acid pairs, enamine-imine pairs, and cyclic forms, in which one proton can occupy two or more positions in a heterocyclic system, such as 1H- and 3H-imidazoles; 1H-, 2H- and 4H-1,2,4-triazoles; 1H- and 2H-isoindoles; and 1H- and 2H-pyrazoles. Tautomeric forms can be in equilibrium or spatially locked into one form by appropriate substitution.
[0081] At various places in this specification, substituents of compounds of the invention are disclosed in groups or ranges. In particular, the invention includes each and every individual subcombination of the members of these groups and ranges. For example, the term "C 1-6 Alkyl (C 1-6 In the present invention, "optionally substituted X" (e.g., optionally substituted alkyl) is particularly used to represent methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl and C6 alkyl, respectively. In the present invention, "optionally substituted X" (e.g., optionally substituted alkyl) is intended to be equivalent to "X, wherein X is optionally substituted" (e.g., "alkyl, wherein the alkyl is optionally substituted"). This does not mean that the feature "X" (e.g., alkyl) itself is optional.
[0082] As used herein, the terms "reduce", "lower", "increase", "increase", or "decrease", "lower" (e.g., with respect to treatment results or effects) have meanings relative to a reference level. In some embodiments, the reference level is a level determined by using the method as a control in an experimental animal model or clinical trial. In some embodiments, the reference level is the level of the same subject before or at the start of treatment. In some embodiments, the reference level is the average level of a population not treated by the treatment method.
[0083] As used herein, the term "effective amount" of a drug (eg, any of the aforementioned conjugates) is an amount sufficient to achieve beneficial or desired results (eg, clinical results), and thus "effective amount" depends on the context in which it is used.
[0084] The term "lower effective dose" when used in conjunction with a drug (e.g., a therapeutic agent) means that the drug dose is therapeutically effective in the combination therapy of the present invention and is lower than the therapeutically effective dose when the drug is used as a monotherapy in a reference experiment or determined by other treatment guidelines.
[0085] As used herein, the term "pharmaceutical composition" refers to a composition containing a compound described herein, which is formulated with a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition is manufactured or sold with the approval of a government regulatory agency as part of a therapeutic regimen for treating a mammalian disease. The pharmaceutical composition can be formulated, for example, for oral administration in a unit dosage form (e.g., tablets, capsules, caplets, capsules, or syrups); for topical administration (e.g., as a cream, gel, lotion, or ointment); for intravenous administration (e.g., as a sterile solution without particulate embolism and a solvent system suitable for intravenous use); or in any other formulation form described herein.
[0086] As used herein, "pharmaceutically acceptable excipients" refers to any ingredient other than the compounds described herein (e.g., an excipient that can suspend or dissolve the active compound) and has the property of being non-toxic and non-inflammatory in the patient. Excipients may include, for example, anti-adherents, antioxidants, binders, coatings, compression aids, disintegrants, dyes (pigments), emollients, emulsifiers, fillers (diluents), film formers or coatings, flavoring agents, fragrances, glidants (flow enhancers), lubricants, preservatives, printing inks, radioprotectants, adsorbents, suspending agents or dispersing agents, sweeteners or water of hydration. Exemplary excipients include, but are not limited to, ascorbic acid, histidine, phosphate buffer, butylated hydroxytoluene (BHT), calcium carbonate, calcium phosphate (dicalcium phosphate), calcium stearate, cross-linked carboxymethylcellulose, cross-linked polyvinyl pyrrolidone, citric acid, cross-linked povidone, cysteine, ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose, magnesium stearate, maltitol, mannitol, methionine, methylcellulose, methylparaben, microcrystalline cellulose, polyethylene glycol, polyvinyl pyrrolidone, povidone, pregelatinized starch, propylparaben, retinyl palmitate, shellac, silicon dioxide, sodium carboxymethylcellulose, sodium citrate, sodium starch glycolate, sorbitol, starch (corn), stearic acid, stearic acid, sucrose, talc, titanium dioxide, vitamin A, vitamin E, vitamin C, and xylitol.
[0087] As used herein, the term "pharmaceutically acceptable salt" means a salt of a compound described herein that is suitable for use in contact with human and animal tissues without unusual toxicity, irritation or allergic reaction within the scope of reasonable medical judgment. Pharmaceutically acceptable salts are well known in the art. For example, pharmaceutically acceptable salts are described in: Berge et al., J. Pharmaceutical Sciences 66: 1-19, 1977 and in Pharmaceutical Salts: Properties, Selection, and Use, (Eds. PHStahl and CGWermuth), Wiley-VCH, 2008. These salts can be prepared in situ during the final isolation and purification of the compounds described herein or prepared separately by reacting the free base with a suitable organic acid.
[0088] The compound may have an ionizable group so that it can be prepared in the form of a pharmaceutically acceptable salt. These salts may be acid addition salts involving inorganic or organic acids or, in the case where the compound is in acidic form, these salts may be prepared from inorganic or organic bases. Typically, these compounds are prepared or used in the form of pharmaceutically acceptable salts, which are prepared as addition products of pharmaceutically acceptable acids or bases. Suitable pharmaceutically acceptable acids and bases are well known in the art, such as hydrochloric acid, sulfuric acid, hydrobromic acid, acetic acid, lactic acid, citric acid or tartaric acid for forming acid addition salts and potassium hydroxide, sodium hydroxide, ammonium hydroxide, caffeine, various amines for forming basic salts. Methods for preparing suitable salts are well-known in the art.
[0089] Representative acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate, undecanoate, valerate, and other salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, and magnesium, as well as nontoxic ammonium, quaternary ammonium, and amine cations including, but not limited to, ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, and ethylamine.
[0090] As used herein, the term "radiopharmaceutical" or "radioconjugate" refers to any compound or conjugate that contains a radioisotope or radionuclide, such as any of the radioisotopes or radionuclides described herein.
[0091] As used herein, the term "radionuclide" refers to an atom (e.g. 3 H. 14 C. 15 N. 18 F. 35 S. 47 Sc, 55 Co. 60 Cu, 61 Cu, 62 Cu, 64 Cu, 67 Cu,75 Br, 76 Br, 77 Br, 89 Zr, 86 Y. 87 Y. 90 Y. 97 Such as 99 Tc, 99m Tc, 105 Rh, 109 Pd, 111 In, 123 I. 124 I. 125 I. 131 I. 149 Pm, 149 Tb, 153 Sm, 166 Ho, 177 Lu, 186 Re, 188 Re, 198 Au, 199 Au, 203 Pb, 211 At 212 Pb, 212 Bi, 213 Bi, 223 Ra, 225 Ac, 227 Th, 229Th , 66 Ga, 67 Ga, 68 Ga, 82 Rb, 117m Sn, 201 Tl). The terms radionuclide, radioisotope or radioisotope may also be used to describe a radionuclide. A radionuclide may be used as a detection agent. In some embodiments, the radionuclide is an alpha-emitting radionuclide. Exemplary radionuclides that may be used in the present invention include, but are not limited to 64 Cu, 67 Cu, 68 Ga, 90 Y. 149 Tb, 153 Sm, 177 Lu, 211 At 212 Bi, 212 Pb, 213 Bi, 223 Ra, 225 Ac and 227 Th.
[0092] As used herein and as is well known in the art, "treatment" of a disorder or condition (e.g., a condition described herein, such as cancer) is a method for obtaining a beneficial or desired result (e.g., a clinical result). Beneficial or desired results may include, but are not limited to, relief or improvement of one or more symptoms or conditions; reduction in the extent of the disease, disorder, or condition; stabilization of the state of the disease, disorder, or condition (i.e., not worsening); prevention of the spread of the disease, disorder, or condition; delay or slowing of the progression of the disease, disorder, or condition; improvement or alleviation of the disease, disorder, or condition; and alleviation (partial or complete), whether detectable or undetectable. In the context of cancer treatment, "improvement" may include, for example, reducing the occurrence of cancer metastasis, reducing tumor volume, reducing tumor vascularization, and / or reducing tumor growth rate. "Relief" of a disease, disorder, or condition refers to a reduction or prolongation of the extent and / or adverse clinical expression of the disease, disorder, or condition and / or the time course of progression compared to the extent or time course in the absence of treatment.
[0093] Checkpoint inhibitors
[0094] In some embodiments, the checkpoint inhibitor is co-administered with a radiopharmaceutical. Typically, suitable checkpoint inhibitors inhibit immunosuppressive checkpoint proteins. In some embodiments, the checkpoint inhibitor inhibits proteins selected from the group consisting of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed death 1 (PD-1), programmed death ligand-1 (PD-L1), LAG-3, T cell immunoglobulin mucin 3 (TIM-3), T cell immune receptor with Ig and ITIM domains (TIGIT), and killer immunoglobulin-like receptor (KIR).
[0095] In some embodiments, the checkpoint inhibitor is capable of binding to CTLA-4, PD-1 or PD-L1. In some embodiments, the checkpoint inhibitor interferes with the interaction between PD-1 and PD-L1 (e.g., interferes with binding).
[0096] In some embodiments, the checkpoint inhibitor is a small molecule.
[0097] In some embodiments, the checkpoint inhibitor is an antibody or an antigen-binding fragment thereof, such as a monoclonal antibody. In some embodiments, the checkpoint inhibitor is a human antibody or a humanized antibody or an antigen-binding fragment thereof. In some embodiments, the checkpoint inhibitor is a mouse antibody or an antigen-binding fragment thereof.
[0098] In some embodiments, the checkpoint inhibitor is a CTLA-4 antibody. Non-limiting examples of CTLA-4 antibodies include BMS-986218, BMS-986249, Ipilimumab, Tremelimumab (formerly known as Tisimumab, CP-675,206), MK-1308, and REGN-4659. Another example of a CTLA-4 antibody is 4F10-11, a mouse monoclonal antibody.
[0099] In some embodiments, the checkpoint inhibitor is a PD-1 antibody. Non-limiting examples of PD-1 antibodies include carrelizumab, cemiplizumab, dotalimumab, nivolumab, pembrolizumab, sintilimab, tislelizumab, and toripalizumab. Another example of a PD-1 antibody is RMP1-14, a mouse monoclonal antibody.
[0100] In some embodiments, the checkpoint inhibitor is a PD-L1 antibody. Non-limiting examples of PD-L1 antibodies include atezolizumab, avelumab, and durvalumab.
[0101] In some embodiments, a combination of more than one checkpoint inhibitor is used. For example, in some embodiments, a CTLA-4 inhibitor and a PD-1 or PD-L1 inhibitor are used.
[0102] Subjects
[0103] In some disclosed methods, a therapy (eg, comprising a therapeutic agent) is administered to a subject. In some embodiments, the subject is a mammal, such as a human.
[0104] In some embodiments, the subject has received or is receiving another therapy. For example, in some embodiments, the subject has received or is receiving a radiopharmaceutical. In some embodiments, the subject has received or is receiving a checkpoint inhibitor.
[0105] In some embodiments, the subject suffers from cancer or has a risk of suffering from cancer. For example, the subject may have been diagnosed with cancer. Cancer may be primary cancer or metastatic cancer. The subject may suffer from cancer at any stage, such as Phase I, Phase II, Phase III or Phase IV, with or without lymph node involvement and with or without cancer metastasis. The provided composition can prevent or reduce the further growth of cancer and / or otherwise improve cancer (such as preventing or reducing cancer metastasis). In some embodiments, the subject does not suffer from cancer but has been determined to have a risk of suffering from cancer, for example, because there are one or more risk factors, such as environmental exposure, one or more genetic mutations or variations, family medical history, etc. In some embodiments, the subject has not been diagnosed with cancer.
[0106] In some embodiments, the cancer is a solid tumor.
[0107] In some embodiments, the solid tumor cancer is breast cancer, non-small cell lung cancer, small cell lung cancer, pancreatic cancer, head and neck cancer, prostate cancer, colorectal cancer, sarcoma, adrenocortical carcinoma, neuroendocrine cancer, Ewing sarcoma, multiple myeloma, or acute myeloid leukemia.
[0108] In some embodiments, the cancer is a non-solid (eg, liquid (eg, blood)) cancer.
[0109] Administration and dosage
[0110] Effective dose and lower effective dose
[0111] The present invention provides combination therapy, wherein the amount of each therapeutic agent may or may not be independently effective in treatment. For example, a method is provided including administering a first therapy and a second therapy in an amount that is effective in treating or improving a condition (e.g., cancer) together. In some embodiments, at least one of the first therapy and the second therapy is administered to the subject at a relatively low effective dose. In some embodiments, the first therapy and the second therapy are both administered at a relatively low effective dose.
[0112] In some embodiments, the first therapy comprises a radiopharmaceutical and the second therapy comprises a checkpoint inhibitor.
[0113] In some embodiments, the first therapy comprises a checkpoint inhibitor and the second therapy comprises a radiopharmaceutical.
[0114] In some embodiments, the therapeutic combination as disclosed herein is administered to a subject in a manner (e.g., an amount and timing of administration) sufficient to cure or at least partially inhibit the symptoms of the disorder and its complications. In the case of a single therapy ("monotherapy"), an amount sufficient to achieve this purpose is defined as a "therapeutically effective amount," i.e., an amount of a compound sufficient to significantly improve at least one symptom associated with a disease or medical condition. A "therapeutically effective amount" generally varies depending on the therapeutic agent. For known therapeutic agents, the relevant therapeutically effective amount may be known to or easily determined by a person skilled in the art.
[0115] For example, in cancer treatment, a drug or compound that reduces, prevents, delays, inhibits or prevents any symptom of a disease or condition will be therapeutically effective. A therapeutically effective amount of a drug or compound does not need to cure the disease or condition, but will provide treatment for the disease or condition so as to delay, hinder or prevent the onset of the disease or condition, or to ameliorate the symptoms of the disease or condition, or to change the stage of the disease or condition or, for example, to be less severe or to speed up recovery in the subject. For example, if the treatment causes the cancer to regress or slow the growth of the cancer, it may be therapeutically effective.
[0116] The dosage regimen effective for these uses (e.g., the amount of each therapeutic agent, the relative time of treatment, etc.) may depend on the severity of the disease or condition and the weight and overall state of the subject. For example, the therapeutically effective amount of a specific composition comprising a therapeutic agent applied to a mammal (e.g., a human) may be determined by a person of ordinary skill in the art taking into account individual differences in age, weight, and condition of the mammal. Because some conjugates of the present invention exhibit enhanced targeting of cancer cells and their residual ability, the dose of these compounds may be less than (e.g., less than or equal to about 90%, 75%, 50%, 40%, 30%, 20%, 15%, 12%, 10%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5% or 0.1%) the equivalent dose required for the therapeutic effect of the unconjugated drug. The therapeutically effective amount and / or the most preferred amount may also be determined empirically by those skilled in the art. Therefore, a lower effective dose may also be determined by those skilled in the art.
[0117] Single or multiple administrations of a radiopharmaceutical or composition (e.g., a pharmaceutical composition comprising a therapeutic agent or radiopharmaceutical) can be performed at a dose and pattern selected by the treating physician. The dose and dosing regimen can be determined and adjusted based on the severity of the subject's disease or condition, and the severity of the subject's disease or condition can be monitored throughout the treatment process according to methods commonly practiced by clinicians or personnel described herein.
[0118] In the disclosed combination therapy methods, the first therapy and the second therapy can be administered to the subject sequentially or simultaneously. For example, a first composition comprising a first therapeutic agent and a second composition comprising a second therapeutic agent can be administered to the subject sequentially or simultaneously. Alternatively, a composition comprising a combination of a first therapeutic agent and a second therapeutic agent can be administered to the subject.
[0119] In some embodiments, the radiopharmaceutical is administered in a single dose. In some embodiments, the radiopharmaceutical is administered more than once, i.e., multiple doses. When the radiopharmaceutical is administered more than once, the doses administered each time may be the same or different.
[0120] In some embodiments, the checkpoint inhibitor is administered in a single dose. In some embodiments, the checkpoint inhibitor is administered more than once, for example, at least twice, at least three times, etc. In some embodiments, the checkpoint inhibitor is administered multiple times according to a conventional or semi-conventional schedule, for example, approximately once every two weeks, once a week, twice a week, three times a week, or more than three times a week. When the checkpoint inhibitor is administered more than once, the dose of each administration may be the same or different. For example, the checkpoint inhibitor can be administered at an initial dose, and the subsequent doses of the checkpoint inhibitor can be higher or less than the initial dose.
[0121] In some embodiments, the first dose of the checkpoint inhibitor is administered simultaneously with the first dose of the radiopharmaceutical. In some embodiments, the first dose of the checkpoint inhibitor is administered before the first dose of the radiopharmaceutical. In some embodiments, the first dose of the checkpoint inhibitor is administered after the first dose of the radiopharmaceutical. In some embodiments, subsequent doses of the checkpoint inhibitor are administered.
[0122] In some embodiments, the invention provides methods comprising administering to a mammal a dose of less than 2 MBq / kg (e.g., less than 1 MBq / kg, less than 750 kBq / kg, less than 500 kBq / kg, less than 400 kBq / kg, less than 300 kBq / kg, less than 250 kBq / kg, less than 200 kBq / kg, less than 150 kBq / kg, less than 100 kBq / kg, or less than 50 kBq / kg) of the mammal's body weight. 225 Each dose may be administered to the mammal multiple times.
[0123] In some embodiments, the 225 The Ac-radiopharmaceutical may be administered at a dose of between 2MBq / kg and 1.5MBq / kg, between 1.5MBq / kg and 1MBq / kg, between 1MBq / kg and 900kBq / kg, between 900kBq / kg and 800kBq / kg, between 800kBq / kg and 700kBq / kg, between 700kBq / kg and 600kq, between 600kBq / kg and 500kBq / kg, between 500kBq / kg and 400kBq / kg, between 400kBq / kg and 300kq, between 300kBq / kg and 200kBq / kg, between 200kBq / kg and 100kBq / kg, or between 100kBq / kg and 50kq. Each dose may be administered to the mammal multiple times.
[0124] In some embodiments, the 225The Ac-radiopharmaceutical can be administered at a dose of about 2 MBq / kg, about 1.9 MBq / kg, about 1.8 MBq / kg, about 1.7 MBq / kg, about 1.6 MBq / kg, about 1.5 MBq / kg, about 1.4 MBq / kg, about 1.3 MBq / kg, about 1.2 MBq / kg, about 1.1 MBq / kg, about 1 MBq / kg, about 0.9 MBq / kg, about 0.8 MBq / kg, about 0.7 MBq / kg, about 0.6 MBq / kg, about 0.5 MBq / kg, about 0.4 MBq / kg, about 0.3 MBq / kg, about 0.2 MBq / kg, about 0.1 MBq / kg, or about 0.05 MBq / kg. Each dose can be administered to the mammal multiple times.
[0125] In some embodiments, the 225 The Ac-radiopharmaceutical is administered at a dose of less than 250 kBq / kg (e.g., about 240 kBq / kg, about 220 kBq / kg, about 200 kBq / kg, about 180 kBq / kg, about 160 kBq / kg, about 150 kBq / kg, about 140 kBq / kg, about 130 kBq / kg, about 120 kBq / kg, about 110 kBq / kg, or about 100 kBq / kg) of the mammal's body weight. Each dose may be administered to the mammal multiple times.
[0126] In some embodiments, the 225 The Ac-radiopharmaceutical is administered at a dose of less than 100 kBq / kg (e.g., about 90 kBq / kg, about 80 kBq / kg, about 70 kBq / kg, about 60 kBq / kg, about 50 kBq / kg, about 40 kBq / kg, about 30 kBq / kg, about 20 kBq / kg, or about 10 kBq / kg) of the mammal's body weight. Each dose may be administered to the mammal multiple times.
[0127] In some embodiments, the 225 The Ac-radiopharmaceutical is administered to the mammal in a unit dose of less than 15 MBq (e.g., about 14 MBq, about 13 MBq, about 12 MBq, about 11 MBq, about 10 MBq, about 9 MBq, about 8 MBq, about 7 MBq, about 6 MBq, about 5 MBq, about 4 MBq, about 3 MBq, about 2 MBq, about 1 MBq). Each unit dose may be administered to the mammal multiple times.
[0128] In some embodiments, the 225 The Ac-radiopharmaceutical is administered to the mammal as a unit dose of less than 10 MBq. Each unit dose may be administered to the mammal multiple times.
[0129] In some embodiments, the 225 The Ac-radiopharmaceutical is administered to the mammal as a unit dose of less than 5 MBq. Each unit dose may be administered to the mammal multiple times.
[0130] In some embodiments, the radiopharmaceutical (or composition thereof) and the checkpoint inhibitor (or composition thereof) are each administered within 28 days (e.g., within 14, 7, 6, 5, 4, 3, 2, or 1 day).
[0131] In some embodiments, the radiopharmaceutical (or a composition thereof) and the checkpoint inhibitor (or a composition thereof) are each administered within 90 days (e.g., within 80, 70, 60, 50, 40, 30, 20, 10, 5, 4, 3, 2, or 1 day). In various embodiments, the checkpoint inhibitor is administered simultaneously with the radiopharmaceutical. In various embodiments, the checkpoint inhibitor is administered multiple times after the first administration of the radiopharmaceutical.
[0132] In some embodiments, a composition (e.g., a composition comprising a radiopharmaceutical) is administered for radiotherapy planning or diagnostic purposes. When administered for radiotherapy planning or diagnostic purposes, the composition can be administered to a subject in an amount effective for diagnosis and / or effective for determining a therapeutically effective dose. In some embodiments, a first dose of a conjugate or a composition thereof (e.g., a pharmaceutical composition) is administered in an amount effective for a radiotherapy plan, followed by administration of a combination therapy comprising a conjugate as described herein and another therapeutic agent.
[0133] Pharmaceutical compositions comprising one or more drugs (e.g., radiopharmaceuticals and / or checkpoint inhibitors) can be formulated for use in various drug delivery systems according to the disclosed methods and systems. One or more physiologically acceptable excipients or carriers may also be included in the composition for appropriate preparations. Examples of suitable preparations can be found in Remington's Pharmaceutical Sciences, Mack Publishing Company, Philadelphia, PA, 17th ed., 1985. For a brief review of drug delivery methods, see, for example, Langer (Science 249: 1527-1533, 1990).
[0134] preparation
[0135] The pharmaceutical composition can be formulated for parenteral, intranasal, topical, oral or local administration, for example, by transdermal means, for preventive and / or therapeutic treatment. The pharmaceutical composition can be administered parenterally (e.g., by intravenous, intramuscular or subcutaneous injection), or by oral ingestion, or by topical application or intraarticular injection in areas affected by vascular or cancer conditions. Examples of other routes of administration include intravascular, intraarterial, intratumoral, intraperitoneal, intraventricular, intradural, and nasal, ocular, intrascleral, intraorbital, rectal, topical, or aerosol inhalation administration. Sustained release administration is also particularly included, for example, by depot injection or erodible implants or components. Suitable compositions include drugs (e.g., compounds as described herein) dissolved or suspended in an acceptable carrier, preferably an aqueous carrier, such as water, buffered water, saline or PBS, etc., for example, for parenteral administration. The composition may contain pharmaceutically acceptable auxiliary substances to approach physiological conditions, such as pH adjusters and buffers, tonicity adjusters, wetting agents or detergents, etc. In some embodiments, the composition is formulated for oral delivery; for example, the composition may contain inert ingredients, such as binders or fillers used to formulate unit dosage forms, such as tablets or capsules. In some embodiments, the composition is formulated for topical administration; for example, the composition may contain inert ingredients, such as solvents or emulsifiers used to formulate creams, ointments, gels, pastes, or eye drops.
[0136] The composition can be sterilized, for example, by conventional sterilization techniques, or aseptically filtered. The aqueous solution can be packaged to be used as is, or lyophilized, and the lyophilized preparation is combined with a sterile aqueous carrier before administration. The pH of the preparation will generally be between 3 and 11, more preferably between 5 and 9 or between 6 and 8, and most preferably between 6 and 7, for example, 6 to 6.5. In some embodiments, the composition in solid form is packaged in a plurality of single dose units, each unit containing a fixed amount of one or more of the above-mentioned drugs, for example, in the form of a sealed package of a tablet or capsule. In some embodiments, the composition in solid form is packaged in a container for flexible use, for example, packaged in a squeezable tube designed for topical use of an applicable cream or ointment.
[0137] Effect
[0138] In some embodiments, the methods of the invention produce a therapeutic effect.
[0139] In some embodiments, the therapeutic effect includes a reduction in tumor volume, a stabilization of tumor volume, or a reduction in the rate of tumor volume growth. In some embodiments, the therapeutic effect includes a reduction in the incidence of recurrence or cancer metastasis.
[0140] Other drugs
[0141] In some embodiments, the disclosed methods further comprise administering an anti-proliferative agent, a radiosensitizer, or an immunomodulator or immunoregulatory agent.
[0142] "Antiproliferative" or "antiproliferative agent" as used interchangeably herein refers to any anticancer agent, including those listed in Table 1, any of which can be used in combination with a radiopharmaceutical to treat a condition or disorder. Antiproliferative agents also include organoplatinum derivatives, naphthoquinone and benzoquinone derivatives, chrysophanol and its anthraquinone derivatives.
[0143] "Immunomodulator" or "immunomodulator" used interchangeably herein refers to any immunomodulator, including those listed in Table 1, any of which can be used in combination with the radiopharmaceuticals provided herein.
[0144] As used herein, "radiosensitizer" includes any drug that increases the sensitivity of cancer cells to radiation therapy. Radiosensitizers may include, but are not limited to, 5-fluorouracil, platinum analogs (e.g., cisplatin, carboplatin, oxaliplatin), gemcitabine, EGFR antagonists (e.g., cetuximab, gefitinib), farnesyl transferase inhibitors, COX-2 inhibitors, bFGF antagonists, and VEGF antagonists.
[0145]
[0146]
[0147]
[0148]
[0149] Example
[0150] Example 1. Synthesis of Radiopharmaceuticals Comprising Compounds of Formula I
[0151] The compound of formula I (including its stereoisomers) is a small molecule antagonist targeting PSMA, which can be used, for example, with lutetium-177 ( 177 Lu) or actinium-225( 225 Ac) is radiolabeled to form a radiopharmaceutical chelated with a radionuclide. The synthesis of the compound of formula I (its stereoisomer) or the corresponding radiopharmaceutical chelated with a radionuclide can be referred to the following documents: Weineisen M, et al., EJNMMI Research, 2014, 4: 63; Weineisen M, et al., J Nucl Med 2015, 56: 1169-1176; US 11,129,912B1; and WO 2018 / 108287 Al.
[0152] The following exemplary compound, Compound A, prepared according to the above document with the indicated stereospecificity was used in the in vivo studies provided in Examples 2 to 5 below.
[0153]
[0154] Example 2. CT-26-mFOLH1 isogenic immunocompetent mouse model 177 Lu]-Compound A Biodistribution
[0155] Using methods well known in the art, compound A of formula I is radiolabeled with Lu-177 to form [ 177 Lu]-compound A. Confirmed using the CT-26-mFOLH1 isogenic model [ 177 Lu]-Compound A's ability to target antigens expressing mouse PSMA-overexpressing tumors in vivo. (The FOLH1 gene encodes PSMA.) Tumor uptake was maintained at 0.5-3% injected dose / g (ID / g) from 6-48 hours post-injection. See Figure 1 .
[0156] Example 3. CT-26-mFOLH1 isogenic immunocompetent mouse model 225 Ac]-Compound A enhanced efficacy
[0157] Compound A of Formula I is radiolabeled using standard techniques to form [ 225 Ac]-Compound A. Using 0.148MBq / kg or 0.444MBq / kg or 0.74MBq / kg or 1.48MBq / kg or 4.44MBq / kg dose (single dose, intravenous) [ 225 Ac]-Compound A was tested in immunocompetent mice [ 225 Ac]-Compound A efficacy study. It was found that at the highest dose tested (4.44 MBq / kg) [ 225 Ac]-Compound A has enhanced efficacy (compared to cold Compound A) in reducing tumor volume in CT-26-mFOLH1 syngeneic mice with an intact immune system. Figure 2 .
[0158] Example 4. 225 Combination of [Ac]-Compound A and α-CTLA-4 / PD-1 treatment produces improved efficacy in the CT-26-mFOLH1 syngeneic mouse model
[0159] In vivo studies were conducted to test the combination of checkpoint inhibitors, α-CTLA-4 and α-PD-1 antibodies. 225Effect of [Ac]-Compound A (as described in Example 3) on relative tumor volume in the CT-26-mFOLH1 mouse model. 225 Improved therapeutic efficacy, including tumor inhibition, was observed when Ac]-Compound A was co-administered at 0.74 MBq / kg (single dose, intravenous) with 5 mg / kg of α-CTLA-4 or α-PD-1. 225 Co-administration of [Ac]-Compound A with both α-CTLA-4 and α-PD-1 resulted in tumor regression and significantly smaller tumor volume compared to treatment in the presence or absence of α-CTLA-4 or α-PD-1. Figure 3A .
[0160] Separately, in vivo studies were performed to test [ 225 Effects of [Ac]-compound A at different doses on relative tumor volume in the CT-26-mFOLH1 mouse model. 225 Improved therapeutic efficacy, including tumor inhibition, was observed when Ac]-Compound A was co-administered at 1.48 MBq / kg (single dose, intravenously) with 5 mg / kg of α-CTLA-4 or α-PD-1 or both, however, this was not as effective as with [ 225 Co-administration of [Ac]-Compound A with both α-CTLA-4 and α-PD-1 resulted in tumor regression and significantly smaller tumor volume compared to treatment in the presence or absence of α-CTLA-4 or α-PD-1. Figure 3B .
[0161] Example 5. 225 Improved overall survival in mice treated with [Ac]-Compound A
[0162] In vivo studies were conducted to test the combination of checkpoint inhibitors, α-CTLA-4 and α-PD-1 antibodies. 225 Ac]-Compound A (as described in Example 3) on the survival rate in the CT-26-mFOLH1 mouse model. 225 When [Ac]-Compound A was co-administered at a dose of 0.74 MBq / kg with 5 mg / kg of α-CTLA-4 or α-PD-1 (or both), the combination treatment resulted in a significantly higher survival rate than the vehicle control group or the monotherapy group ([ 225 Ac]-Compound A) improved overall survival rate. Figure 4A .
[0163] Separately, in vivo studies were performed to test [ 225Effect of [Ac]-compound A at different doses on survival in the CT-26-mFOLH1 mouse model. 225 When Ac]-Compound A was co-administered at a dose of 1.48 MBq / kg with 5 mg / kg of α-CTLA-4 or α-PD-1 (or both), the combination treatment resulted in improved overall survival. Figure 4B .
[0164] Other embodiments
[0165] Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation many equivalents to the specific embodiments described herein. Such equivalents are intended to be encompassed by the claims.
Claims
1. A method for treating a mammal having a cancer that expresses prostate specific membrane antigen (PSMA), the method comprising: (i) administering to the mammal 225 Ac-radiopharmaceutical, wherein the mammal has received or is receiving one or more checkpoint inhibitors; (ii) administering one or more checkpoint inhibitors to the mammal, wherein the mammal has received or is receiving 225 Ac-radiopharmaceutical; or (iii) administering to the mammal 225 Ac-radiopharmaceutical and administering to the mammal one or more checkpoint inhibitors simultaneously. wherein in each case, the 225 Ac-radiopharmaceuticals comprise a compound of formula I or a stereoisomer thereof chelated with 225 Ac:
2. The method of claim 1, comprising administering to the mammal one or more checkpoint inhibitors, wherein the mammal has received or is receiving 225 Ac-radiopharmaceutical.
3. The method of claim 1 or 2, wherein said 225 Ac-radiopharmaceuticals contain chelated 225 Ac:
4. The method of any one of claims 1 to 3, wherein the one or more checkpoint inhibitors comprise a PD-1 or PD-L1 inhibitor or a CTLA-4 inhibitor.
5. The method of claim 4, wherein the PD-1 or PD-L1 inhibitor or the CTLA-4 inhibitor is an antibody.
6. The method of any one of claims 1 to 3, wherein the one or more checkpoint inhibitors include a PD-1 or PD-L1 inhibitor and a CTLA-4 inhibitor.
7. The method of any one of claims 4 to 6, wherein the PD-1 or PD-L1 inhibitor is selected from the group consisting of: carrelizumab, cemiplizumab, dotalimumab, nivolumab, pembrolizumab, sintilimab, tislelizumab, toripalimab, RMP1-14, atezolizumab, avelumab and durvalumab.
8. The method of any one of claims 4 to 6, wherein the CTLA-4 inhibitor is selected from the group consisting of: BMS-986218, BMS-986249, ipilimumab, tremelimumab (formerly known as tesimumab, CP-675,206), MK-1308, REGN-4659, and 4F10-11.
9. A method as claimed in any preceding claim, wherein the mammal is a human.
10. A method as claimed in any one of the preceding claims, wherein the 225 The Ac-radiopharmaceutical is administered at a dose of less than 2 MBq / kg body weight of said mammal.
11. A method as claimed in any one of the preceding claims, wherein the 225 The Ac-radiopharmaceutical is administered at a dose of less than 750 kBq / kg body weight of said mammal.
12. A method as claimed in any one of the preceding claims, wherein the 225 The Ac-radiopharmaceutical is administered at a dose of less than 250 kBq / kg body weight of said mammal.
13. A method as claimed in any one of the preceding claims, wherein the 225 The Ac-radiopharmaceutical is administered to the mammal in a unit dose of less than 15 MBq.
14. A method as claimed in any one of the preceding claims, wherein the 225 The Ac-radiopharmaceutical is administered to the mammal in a unit dose of less than 10 MBq.
15. A method as claimed in any one of the preceding claims, wherein the 225 The Ac-radiopharmaceutical is administered to the mammal in a unit dose of less than 5 MBq.
16. The method of any of the preceding claims, wherein the cancer is selected from the group consisting of prostate cancer, breast cancer, colorectal cancer, renal cell carcinoma, bladder cancer, testicular embryonal carcinoma, neuroendocrine cancer, and brain tumors.
17. The method of claim 16, wherein the cancer is prostate cancer or breast cancer.
18. The method of any one of the preceding claims, wherein the administration results in a reduction in tumor volume, a stabilization of tumor volume, or a reduction in the rate of increase of tumor volume.
19. The method of claim 18, wherein the administering results in a reduction in the occurrence of recurrence or metastasis.
20. The method of claim 1, comprising administering to the mammal one or more checkpoint inhibitors, wherein the mammal has received or is receiving a drug comprising a chelated 225 Ac 225 Ac-radiopharmaceuticals: The one or more checkpoint inhibitors include a PD-1 inhibitor and a CTLA-4 inhibitor, and wherein 225 The Ac-radiopharmaceutical is administered at a dose of 0.5-1.5 MBq / kg body weight of said mammal.
